Trial: 202006127

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors

Phase

I/II

Principal Investigator

Adkins, Douglas

Disease Site

Esophagus; Ill-Defined Sites; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lung Cancer – Small Cell; Stomach

Learn more about this study at: clinicaltrials.gov